Venous thromboembolism and hyperhomocysteinemia as first manifestation of pernicious anemia;Tromboembolia venosa e hiperhomocisteinemia como primera manifestación de una anemia perniciosa

Revista Clinica Espanola

Volumn 205, Issue 10, 2005, Pages 489-492

  Fernandez Miranda C ^a   Yebra Yebra, M ^a   Ribera Casado, C ^a   Toledo Urgarte, T ^a   Martin Mola M ^a   Gomez Gonzalez P ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Hyperhomocysteinemia; Oral vitamin B12; Pernicious anemia; Venous thromboembolism

Indexed keywords

CYANOCOBALAMIN; HOMOCYSTEINE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL FEATURE; COMORBIDITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; LABORATORY DIAGNOSIS; LUNG EMBOLISM; MACROCYTIC ANEMIA; MAJOR CLINICAL STUDY; MALE; PERNICIOUS ANEMIA; PREVALENCE; SCHILLING TEST; VENOUS THROMBOEMBOLISM;

EID: 27944476897     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1157/13079763     Document Type: Article

References (15)

1. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325:1202-6.
2. Fernández-Miranda C, Paz M, Aranda JL, Nuñez V, Gómez P, Díaz-Rubio P, et al. Homocisteína y progresión de la aterosclerosis de la arteria carótida en pacientes con enfermedad coronaria. Med Clin (Barc). 2003;121: 561-4.
3. Aguirre Errasti C, Egurbide Arberas MV. Significado clínico de la homocisteína. Rev Clin Esp. 2001;201:25-7.
4. 12 and/or folate deficiency: role of hyperhomocysteinemia. Ann Hematol. 2002; 81:616-21.
5. Epstein FH. Pernicious anemia. N Engl J Med. 1997;337;20:1441-8.
6. Savage DG, Lindenbaum J, Stabler SP, Allen RH. Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. Am J Med. 1994;96:239-46.
7. Hervé Levesque IM, Lecam-Duchez V, Borg JY, Ducrotté P, Philippe C. Mesentric venous thrombosis revealing both factor II G20210A mutation and hyperhomocysteinemia related to pernicious anemia. Gastroenterology. 2000;118:237-8.
8. Caldera A, Mora J, Kotler M, Eiger G. Pulmonary embolism in a patient with pernicious anemia and hyperhomocysteinemia. Chest. 2002;122:1487-8.
9. Kharchafi A, Oualim Z, Amezyane T, Mahassin F, Ghafir D, Ohayon V, et al. Maladie de Biermer et thrombose veineuse. À propos de deux observations. Rev Med Interne. 2002;23:563-6.
10. Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. JAMA. 1997;277:1775-81.
11. 12 deficiency. Br J Nutr. 2003;89:439-41.
12. De Bree A, Verschuren WM, Bjorke-Monsen AL, Van der Put NM, Heil SG, Trijbels FJ, et al. Effect of the methylenetetrahydrofolate reductase 677C → T mutation on the relations among folate intake and plasma folate and homocysteine concentrations in a general population sample. Am J Clin Nutr. 2003;77:687-93.
13. Kuzminski AM,del Glacco EJ, Allen RH, Stabler SP, Lindenbaum J. Effective treatment of cobalamin deficiency with oral cobalamin. Blood. 1998; 92:1191-8.
14. Elia M. Oral or parenteral therapy for B12 deficiency. Lancet. 1998; 352:1721-2.
15. 12. Med Clin (Barc). 2001;116:457-8.